Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (41-50 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Case Report: response to ipilimumab in a patient with HIV with metastatic melanomaMatthew M Burke, Harriet M Kluger, Marjorie Golden, et al.
Clinical Chemistry|May 19, 2017
The Phoenix Rises: The Rebirth of Cancer ImmunotherapyIvan M Blasutig, Sofia Farkona, Elizabeth I Buchbinder, et al.
Diabetes Care|March 26, 2015
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapyJing Hughes, Nalini Vudattu, Mario Sznol, et al.
Journal for Immunotherapy of Cancer|March 2, 2020
Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting reportCatarina Pinto, Michael Bergmann, Daria Briukhovetska, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2004
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancerYun Yen, Kim Margolin, James Doroshow, et al.
American Journal of Clinical Oncology|August 25, 2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain MetastasesHaruka Uezono, David Nam, Harriet M Kluger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancerMary M McCarthy, Mario Sznol, Kyle A DiVito, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 6, 2008
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancerNicolas Acquavella, Harriet Kluger, John Rhee, et al.
Journal of Neurosurgery|June 19, 2012
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survivalJonathan P S Knisely, James B Yu, Jaclyn Flanigan, et al.
Cancer|April 28, 2011
A phase 2 trial of dasatinib in advanced melanomaHarriet M Kluger, Arkadiuz Z Dudek, Carrie McCann, et al.
Pageof 19

Showing results (41-50 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Case Report: response to ipilimumab in a patient with HIV with metastatic melanomaMatthew M Burke, Harriet M Kluger, Marjorie Golden, et al.
Clinical Chemistry|May 19, 2017
The Phoenix Rises: The Rebirth of Cancer ImmunotherapyIvan M Blasutig, Sofia Farkona, Elizabeth I Buchbinder, et al.
Diabetes Care|March 26, 2015
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapyJing Hughes, Nalini Vudattu, Mario Sznol, et al.
Journal for Immunotherapy of Cancer|March 2, 2020
Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting reportCatarina Pinto, Michael Bergmann, Daria Briukhovetska, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2004
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancerYun Yen, Kim Margolin, James Doroshow, et al.
American Journal of Clinical Oncology|August 25, 2021
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain MetastasesHaruka Uezono, David Nam, Harriet M Kluger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancerMary M McCarthy, Mario Sznol, Kyle A DiVito, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 6, 2008
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancerNicolas Acquavella, Harriet Kluger, John Rhee, et al.
Journal of Neurosurgery|June 19, 2012
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survivalJonathan P S Knisely, James B Yu, Jaclyn Flanigan, et al.
Cancer|April 28, 2011
A phase 2 trial of dasatinib in advanced melanomaHarriet M Kluger, Arkadiuz Z Dudek, Carrie McCann, et al.
Pageof 19